Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).

Contraindications

• Allergy to sulfonylureas or sulfonamidess

• Diabetes mellitus type 1

• Diabetic ketoacidosis

• Patients that underwent removal of the pancreas

• Acute porphyria

• Severe liver disease accompanying with liver insufficiency

• Several conditions (e.g., infectious diseases or major surgical intervention), when insulin administration is required

• Pregnancy or breastfeeding

Pharmacokinetics

Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy.

References